mRNA-Based CAR T-Cell Therapy Descartes-11 Moves Into Phase 2 Trial in Myeloma
Multiple myeloma is the second most common hematological malignancy in the world and remains difficult to treat despite numerous therapeutic advances and drug approvals. Patients continue to experience multiple relapses and complications of the disease, affecting many areas of the body, such as the bones, kidneys and immune system. An mRNA-based CAR-T cell therapy, named […]
